Post-Marketing Registry, Suicidality Warning Could Be Paradox For Siliq

Labeling for Valeant’s pending plaque psoriasis treatment might warn about the potential for suicide; if that's effective, though, will the company be able to enroll meaningful numbers of patients in its registry that aims for a definitive answer?

Valeant Headquarters

More from US FDA Performance Tracker

More from Regulatory Trackers